Melanie Cree, [associate professor of pediatrics at University of Colorado School of Medicine and] a pediatric endocrinologist [and director, Multi-Disciplinary PCOS Clinic] at Children’s Hospital Colorado, is one physician looking into this question. Working with her colleagues, she conducted a randomized trial testing semaglutide, the ingredient in Novo Nordisk’s Rybelsus and Wegovy, in women and adolescents with polycystic ovary syndrome, or PCOS.